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Background: Hyperoxia is shown to impair airway relaxation via limiting L-arginine bioavailability to nitric oxide
synthase (NOS) and reducing NO production as a consequence. L-arginine can also be synthesized by L-citrulline
recycling. The role of L-citrulline supplementation was investigated in the reversing of hyperoxia-induced impaired
relaxation of rat tracheal smooth muscle (TSM).
Methods: Electrical field stimulation (EFS, 2–20 V)-induced relaxation was measured under in vitro conditions in
preconstricted tracheal preparations obtained from 12 day old rat pups exposed to room air or hyperoxia
(>95% oxygen) for 7 days supplemented with L-citrulline or saline (in vitro or in vivo). The role of the
L-citrulline/L-arginine cycle under basal conditions was studied by incubation of preparations in the presence of
argininosuccinate synthase (ASS) inhibitor [α-methyl-D, L-aspartate, 1 mM] or argininosuccinate lyase inhibitor (ASL)
succinate (1 mM) and/or NOS inhibitor [Nω-nitro-L-arginine methyl ester; 100 μM] with respect to the presence or
absence of L-citrulline (2 mM).
Results: Hyperoxia impaired the EFS-induced relaxation of TSM as compared to room air control (p < 0.001;
0.5 ± 0.1% at 2 V to 50.6 ± 5.7% at 20 V in hyperoxic group: 0.7 ± 0.2 at 2 V to 80.0 ± 5.6% at 20 V in room air group).
Inhibition of ASS or ASL, and L-citrulline supplementation did not affect relaxation responses under basal
conditions. However, inhibition of NOS significantly reduced relaxation responses (p < 0.001), which were restored
to control level by L-citrulline. L-citrulline supplementation in vivo and in vitro also reversed the hyperoxia-impaired
relaxation. The differences were significant (p <0.001; 0.8 ± 0.3% at 2 V to 47.1 ± 4.1% at 20 V without L-citrulline;
0.9 ± 0.3% at 2 V to 68.2 ± 4.8% at 20 V with L-citrulline). Inhibition of ASS or ASL prevented this effect of L-citrulline.
Conclusion: The results indicate the presence of an L-citrulline/L-arginine cycle in the airways of rat pups.
L-citrulline recycling does not play a major role under basal conditions in airways, but it has an important role
under conditions of substrate limitations to NOS as a source of L-arginine, and L-citrulline supplementation reverses
the impaired relaxation of airways under hyperoxic conditions.
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Bronchopulmonary dysplasia (BPD) is a chronic respiratory
disease that results from complications related to the lung
injury during treatment of respiratory distress syndrome in
premature babies. Increased airway reactivity in childhood
is the most common long-term manifestation of neonatal
lung injury and is pronounced when there is a history of
BPD [1,2]. While a variety of pre- and postnatal inflamma-
tory processes may contribute to its etiology, exposure of
an immature respiratory tract to increased supplemental
oxygen plays an important contributing role to the devel-
opment of BPD [3]. Therefore, neonatal hyperoxic expos-
ure may serve as a model for BPD in which enhanced
airway reactivity is a well-known consequence. We and
others have demonstrated in rat pups that exposure to high
inspired oxygen is associated with many pathophysiological
features of BPD, including increased contractile responses
and decreased relaxant responses of airways under in vitro
and in vivo conditions using trachea and lung parenchymal
tissues, as well as changes in lung morphology [4-11].
Nitric oxide (NO) is a potent relaxant of airway smooth
muscle (ASM) [12,13]. Exposure of rat pups to high oxygen
concentration has been shown to impair relaxant responses
of the tracheal smooth muscle (TSM) [8] and the distal air-
ways using lung parenchymal tissue [4,5]. The decreased
NO production was implicated in hyperoxia-induced im-
pairment of relaxation of airways NO-cGMP-dependent
mechanism (14). In order to compensate for the decrease
of endogenous NO in neonatal care, exogenous NO is fre-
quently used to prevent the adverse effects of neonatal
hyperoxia [14-16]. Recent randomized human trials sug-
gest that inhaled NO (iNO) decreases the incidence of
BPD in subsets of premature babies [3,17,18]. However,
inconsistent efficacy [19], complexity of iNO delivery in
nonintubated patients, and high cost provide rationales for
efficacious alternatives to iNO.
As NO is produced from L-arginine via NO synthase
(NOS) [20], bioavailability of L-arginine plays a key role
in the production of NO and on lung function. In most
cells, L-arginine requirements are met primarily by the
uptake of extracellular L-arginine via specific cationic
amino acid transporters (system y+) [21]. However, in
NO-producing cells, L-arginine may also be obtained
through the L-citrulline/L-arginine cycle [22]. Through this
cycle, L-citrulline can be recycled as L-arginine to the NOS
pathway by the successive action of argininosuccinate syn-
thase (ASS), which converts L-citrulline and L-aspartate
into L-argininosuccinate, and then the argininosuccinate
lyase (ASL) hydrolyses L-argininosuccinate into L-arginine
and fumarate [22-25], (Figure 1). Some authors suggest that
L-citrulline might be an indirect precursor of NO in NO-
synthesizing cells [26]. L-citrulline has been shown to re-
store impaired relaxation of airways after early asthmatic
reaction [27]. Also in other tissues, including the opossuminternal anal sphincter and rat gastric fundus, it has been
shown that the L-citrulline/L-arginine cycle is involved in
inhibitory nonadrenergic-noncholinergic nerve (iNANC)-
mediated smooth muscle relaxation, under conditions of
limited L-arginine availability to nNOS, which is induced by
competitive inhibitors of the enzyme [28-31]. Furthermore, it
was demonstrated that L-citrulline prevents O2-inducing
alveolar damage and alters angiogenesis in developing lungs
[11]. However, there are no studies showing the role of the
L-citrulline/L-arginine cycle on hyperoxia-induced impair-
ment of ASM relaxation. The study of L-citrulline becomes
even more important in hyperoxic condition because, due to
the increased arginase activity [32], conditions of limited
L-arginine availability for NOS are created. Therefore, this
study was undertaken to test the hypothesis that the
L-citrulline/L-arginine cycle is active in rat pup airways and
that L-citrulline supplementation will reverse hyperoxia-
induced impaired relaxation of ASM.
Methods
Animals and tissue preparation
Sprague–Dawley rat pups were used for these experiments.
On the 5th day of life (P5), weight-matched rat pups from
different litters were randomly mixed and assigned to either
hyperoxic (n=32) or room air (n=43) groups. We have
shown earlier that hyperoxic exposure for seven days start-
ing from day 5 shows BPD-like symptoms in rat pups [4].
Therefore, the pups were exposed to hyperoxia (>95% O2)
or room air for seven days. Hyperoxic animals were housed
in a Plexiglas chamber and exposed to a continuous flow of
O2 (2 L/min), whereas control animals were kept in a com-
mercial rat cage in room air. Mothers were rotated each
day between room air and hyperoxic groups to protect
them from the toxicity of a constant hyperoxic exposure.
Oxygen concentration was monitored continuously via oxy-
gen analyzer (Pro O2 Nuvair, Oxnard, CA). In one set of
experiments, the animals were injected intraperitoneally
(i.p.) with 200 mg/kg/day L-citrulline during hyperoxic ex-
posure. Control animals were injected with the same
volume of saline. No differences in weight were observed
between the compared groups.
Animals were euthanized by asphyxiation in CO2 on day
12 of postnatal life (P12). The trachea was removed and
prepared with the intact epithelium, free of serosal con-
nective tissue, in an ice-cold oxygenated Krebs-Henseleit
(KH) solution (concentration in mM: 118.2 NaCl, 25
NaHCO3, 4.6 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.5 CaCl2, and
10% dextrose, pH=7.4). A cylindrical airway segment of
3-mm length was isolated from the mid-portion of the
tracheas of each animal, and then suspended between a
stainless hook at the bottom of the organ bath and a force
displacement transducer (FT 03 C, Grass Instruments,
Quincy, MA). TSM tension was measured by a Power




L-ornithine  + urea
Proline Polyamine
ODC















Figure 1 Schematic presentation of the role of L-citrulline/L-arginine cycle in the regulation of airway function. The diagram integrates
physiologic, biochemical and molecular mechanisms whereby neonatal hyperoxic exposure impairs NO-cGMP signaling and resultant airway
smooth muscle relaxation. The L-arginine is a common substrate for NOS and arginase. Hyperoxia increases the lung arginase activity that
reduces the bioavailability of L-arginine to NOS. L-citrulline is recycled to L-arginine through ASS and ASL enzymes. It is proposed that L-citrulline
competes with NOS blockers (like L-NAME). However, it blocks arginase activity in hyperoxic conditions and thus increases the bioavailibility of
L-arginine. The red lines with bars indicate inhibition. ASS, argininosuccinate synthase; ASL, argininosuccinate lyase; CATs, cationic amino acid
transporters; cGMP, cyclic guanosine monophosphate; GDP, guanosine diphosphate; GTP, guanosine triphosphate; L-NAME, Nω-nitro-L-arginine
methyl ester; NO, nitric oxide; NOS, nitric oxide synthase; OAT, ornithine amino transferase; ODC, ornithine decarboxylase; PKG, protein kinase G;
sGC, soluble guanylate cyclase.
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then tissues were allowed to equilibrate for 40 min in the
organ baths containing KH solution (20 ml) at 37°C. The so-
lution was continuously aerosolized with a gas mixture of
95% O2 and 5% CO2. All protocols described in this study
were approved by the Internal Animal Use and Care
Committees of the University of Prishtina and Case Western
Reserve University.
Electrical field stimulation-induced relaxation experiments
After equilibration, a cumulative concentration-response
curve was made to find the concentration of bethanechol
that elicited 50–75% of maximal response in TSM (100 μM
bethanechol). Incremental electrical field stimulation (EFS)
was applied for 10s at 2-min intervals to induce relaxation
through platinum electrodes to preconstricted TSM at
various voltages (2–20 V, AC). The relaxation of cylinders
after EFS was expressed as a percentage of the total precon-
stricted state for each cylinder [4].
An NOS inhibitor – Nω-nitro-L-arginine methyl ester
(L-NAME; 100 μM) and L-citrulline (2 mM) were applied to
the organ bath 30 min prior to the addition of bethanechol,
while an ASS inhibitor–α-methyl-D,L-aspartate (α-MDLA;1 mM) and an ASL inhibitor–succinate (1 mM) were applied
40 min before bethanecol.
Statistical analysis
The results are expressed as mean±SEM. Statistical signifi-
cance was determined by Two-way ANOVA with repeated
measurements. To analyze the differences in treatments at
different voltage settings between groups and within a
group, a post-hoc Tukey–Kramer multiple comparison test
was used. In all cases, p < 0.05 was considered statistically
significant.
Results
Effect of hyperoxia on ASM relaxation
Consistent with our previous studies, EFS-induced
relaxation increased with the increasing voltages and
hyperoxia significantly reduced the EFS-induced relax-
ation of preconstricted TSM (n= 10) as compared to
room air (p < 0.001; n = 10). The relaxant responses in
the hyperoxic group ranged from 0.5 ± 0.1% at 2 V to
50.6 ± 5.7% at 20 V while those in the control group
ranged from 0.7 ± 0.2% at 2 V to 80.0 ± 5.6% at 20 V)































Figure 2 Effect of hyperoxia on EFS-induced TSM relaxation:
EFS-induced relaxation of TSM was impaired in tissues obtained
from rat pups exposed to hyperoxia as compared to those from
room air exposed rat pups. *Room air vs. hyperoxic rat pups (n= 10
for each group). *p < 0.05; ***p < 0.001.
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tween incremental voltages within the groups (p < 0.01).
Role of L-citrulline, α-MDLA and succinate on EFS-induced
TSM relaxation in room air-exposed animals
To study the role of the L-citrulline/L-arginine cycle under
basal conditions, the tissues were incubated with L-citrulline
(2 mM), or α-MDLA (1 mM), or succinate (1 mM), or in
combination of L-citrulline with succinate. There was no
effect of L-citrulline on the EFS-induced relaxation of pre-
constricted TSM of rat pups when compared to control
responses (n= 7 per group). The α-MDLA, succinate or
combination of L-citrulline and succinate did not produce
any significant effect on EFS-induced relaxant responses
(n=7 per group). The relaxation values of TSM obtained
from control tissues ranged from 1.1 ± 0.4% at 2 V to
78.1± 4.0% at 20 V (Figure 3). These data indicate that the
L-citrulline/L-arginine cycle does not play a major role in
the airway relaxation of rat pups under basal conditions
(Figure 3).
Effect of L-citrulline, α-MDLA, and succinate on TSM
relaxation after NOS blockage in room air-exposed
animals
To study the effect of L-citrulline recycling under condi-
tions of reduced utilization of L-arginine by NOS, tracheal
rings obtained from the room air-exposed animals (n=8)
were preincubated with an NOS inhibitor–L-NAME
(100 μM), and then constricted using bethanecol. L-NAME
significantly reduced (p<0.01) the EFS-induced relaxation
of TSM compared to the control responses, particularly at
higher voltages (8–20 V; p <0.01), (Figure 4). The data ran-
ged from 0.7±0.2% at 2 V to 50.5± 7.2% at 20 V, whereas
in the control responses, the data ranged from 0.5±0.2% at
2 V to 78.0 ±4.9% at 20 V. Incubation of tissues with
L-citrulline (2 mM) reversed the inhibition of EFS-induced
relaxation of TSM produced by L-NAME (p<0.01), indi-
cating a critical role of L-citrulline under limitingconditions of NO production. These data ranged from
0.6±0.1% at 2 V to 72.1 ±4.0% at 20 V, (Figure 4).
α-MDLA (1 mM) prevented the capability of L-citrulline to
restore diminished relaxant responses of TSM due to
L-NAME. These differences were significant (p< 0.01)
when compared to responses obtained from tissues coincu-
bated in L-NAME plus L-citrulline. The data ranged
from 0.4±0.2% at 2 V to 52.3± 5.2% at 20 V. Similarly,
succinate significantly (p <0.01) prevented the effect of
L-citrulline to restore the reduced relaxant responses of
TSM due to L-NAME. The data ranged from 0.8±0.4% at
2 V to 57.9± 4.7% at 20 V (Figure 5).
Effect of L-citrulline, α-MDLA and succinate on TSM
relaxation in hyperoxia-exposed rat pups
As shown above, hyperoxia impaired the EFS-induced re-
laxation of rat pup TSM (p<0.001) as compared to room
air-exposed animals (n=7 per group). The data ranged
from 0.8±0.3% at 2 V to 47.1±4.1% at 20 V in hyperoxic
animals and 0.9±0.2% at 2 V to 74.8±5.6% at 20 V in room
air animals. L-citrulline supplementation (2 mM) reversed
the hyperoxia-induced impaired relaxation (p<0.001). The
data ranged 0.9±0.3% at 2 V to 68.2±4.8% at 20 V
(in hyperoxia+L-citrulline group) The differences were sig-
nificant at higher voltages≥8 V (p<0.001). Both the ASS in-
hibitor, α-MDLA (1 mM) and the ASL inhibitor, succinate
(1 mM) prevented L-citrulline from reversing the hyperoxia-
induced impairment of relaxant responses (Figure 6 and
Figure 7). The data ranged from 0.6±0.1% at 2 V to
53.1±3.5% at 20 V (in the presence of α-MDLA) and from
0.7±0.2% at 2 V to 47.9±4.1% at 20 V (in the presence of
succinate), respectively.
Intraperitoneal supplementation of L-citrulline reversed
the hyperoxia-induced impaired relaxation
As shown in Figure 8 i.p. supplementation of rat pups with
L-citrulline (200 mg/kg/day) reversed the impaired relax-
ation in hyperoxic animals to normal levels compared to
hyperoxic controls (p <0.01). The differences were signifi-
cant at higher voltages (≥ 12 V).
Discussion
Prior research by us has shown that the long-term exposure
of hyperoxia impairs airway relaxation [4,32] and enhances
airway contraction in neonatal rat lung [5]. In this study we
have shown that hyperoxia decreases EFS-induced relaxant
responses of ASM. Both of these processes complement
each other in increasing airway hyperreactivity. Hyperoxia
increases arginase activity, which limits the availability of
L-arginine to NOS [4]. Limitation of L-arginine, being a
common substrate for arginase and NOS, disrupts the NO/
cGMP signaling pathway, resulting in impaired relaxation
[4,32]. In our recent publication we have shown that pro-
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Figure 3 Role of L-citrulline, α-MDLA, and succinate on EFS-induced relaxation of TSM of rat pups exposed to room air: No significant
effect of L-citrulline, α-MDLA and L-succinate individually or in combination was observed in TSM of room air exposed rat pups (n= 7 for each
protocol of the experiments).
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substrate for NOS and is obtained from different sources
for the production of NO, including the recycling of
L-citrulline [31]. Maarsingh et al. [27] have shown the exist-
ence of an L-citrulline/L-arginine cycle in TSM. We have
observed that the supplementation of L–citrulline reversed
the hyperoxia-induced impaired relaxation in both in vivo
(i.p. administration to animals) and in vitro (addition to organ
bath) conditions. The in vitro study indicates that in rat TSM,
there is an active L-citrulline/L-arginine cycle that pro-
duces L-arginine. Since the systemic administration of
L-citrulline via i.p. route is also effective, we assume that,
unlike L-arginine, L-citrulline is not taken up by the liver
from the portal circulation, but is metabolized in the kidney
to L-arginine that increases the plasma concentration of
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Figure 4 Effect of L-citrulline and α-MDLA on TSM relaxation after NO
from room air-exposed rat pups was significanlty (p < 0.01) reduced by the
L-NAME was returned to normal levels by the addition of L-citrulline (2 mM
prevented the capability of L-citrulline to recover the diminished relaxation
air + L-NAME+ L-citrulline vs. Room air + L-NAME; † Room air + L-NAME+ L-citr
}}p< 0.01; †p< 0.05; ††p< 0.01. (n= 8 for each protocol of the experimentsof L-citrulline could be a better substitute for L-arginine as
it bypasses the liver [22].
The inhibition of the enzymes (ASL and ASS) involved
in the recycling pathway of L-citrulline to L-arginine did
not affect EFS-induced relaxation of TSM under basal con-
ditions, indicating that L-arginine in basal conditions is not
a limiting substrate. Furthermore, the supplementation of
TSM with exogenous L-citrulline did not affect EFS-induced
relaxation, indicating that the supply of L-arginine for NOS
through L-citrulline cycling is not an important source for
NOS substrate under these conditions. However, this path-
way appears to play a key role once the NOS enzyme is
blocked. Interestingly, L-citrulline supplementation fully
restored the reduced relaxation caused by the blockage of
NOS under basal conditions. The effect of L-citrulline was
more prominent particularly at higher voltages when an12 16 20
EFS (V)
lline
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). The argininosuccinate synthase (ASS) inhibitor – α-MDLA (1 mM)
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Figure 5 Effect of L-citrulline and succinate on TSM relaxation after NOS blockage: EFS-induced relaxtion of TSM preparations obtained
from room air-exposed rat pups was significanlty (p < 0.01) reduced by the addition of 100 μM L-NAME. The decrease in relaxation due to
L-NAME was returned to normal levels by the addition of L-citrulline (2 mM). The argininosuccinate lyase (ASL) inhibitor – succinate (1 mM)
prevented the capability of L-citulline to recover the diminished relaxation responces due to L-NAME. * Room air + L-NAME vs. Room air; } Room
air + L-NAME+ L-citrulline vs. Room air + L-NAME; † Room air + L-NAME+ L-citrulline + succinate vs. Room air + L-NAME+ L-citrulline. **p < 0.01; }p< 0.05;
}}p< 0.01; †p< 0.05; ††p< 0.01. (n= 8 for each protocol of the experiments).
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This observation suggests that L-citrulline competes with the
NOS blocker (L-NAME) reversing its inhibitory effects.
These findings are comparable with other studies performed
in the tracheal rings of a guinea pig model of asthma and
human ASM using single or multiple frequencies of EFS
[3,27], where the inhibitory effect of NOS inhibitor, Nω-
nitro-L-arginine, on NO-mediated iNANC relaxation was
restored by L-citrulline as well as L-arginine [33]. In
addition, the inhibition of ASL reversed this beneficial effect
of L-citrulline supplementation, indicating the presence of
an active L-citrulline/L-arginine cycle in the airways of rat
pups under conditions of substrate limitation for NO pro-
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Figure 6 Effect of L-citrulline and inhibition of argininosuccinate synt
L-citrulline supplementation (2 mM) reversed the hyperoxia-induced impair
lost when TSM was incubated in the presence of argininosuccinate synthas
Hyperoxia + L-citrulline vs. Hyperoxia; †Hyperoxia + L-citrulline + α-MDLA vs. Hyp
(n= 7 for each protocol of the experiments).In asthmatic patients, a decrease in plasma L-arginine levels
and an increase in serum arginase activity was observed [34].
Similarly, in the experimental BPD in neonatal rats, the
plasma level of L-arginine was found to have decreased after
hyperoxic exposure of animals [11], while arginase protein
expression was upregulated in the airway epithelium, fur-
ther depriving the adjacent ASM for L-arginine substrate.
Furthermore, Malleske et al. [35] showed that hyperoxia
diminishes NO production in mice because of the increase
in hepatic arginase activity. L-citrulline also plays a key
role in the reversal of impaired relaxation during
hyperoxia that creates a L-arginine limiting condition.
L-citrulline has been reported to be a noncompetitive in-
hibitor of arginase [36]. Therefore, in hyperoxic condi-
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Figure 7 Effect of L-citrulline and inhibition of argininosuccinate lyase (ASL) on TSM relaxation in hyperoxia-exposed rat pups: The
addition of 2 mM L-citrulline reversed the hyperoxia-induced impairment of relaxation of TSM (p < 0.001). The effect of the L-citrulline was lost
when TSM was incubated in the presence of argininosuccinate lyase (ASL) inhibitor, L-succinate (1 mM) (p < 0.01). *Hyperoxia vs. Room air; }
Hyperoxia + L-citrulline vs. Hyperoxia; †Hyperoxia + L-citrulline + succinate vs. Hyperoxia + L-citrulline. *p < 0.05; ***p< 0.001; }}p< 0.01; }}}p< 0.001;
†p< 0.05; ††p< 0.01(n= 7 for each protocol of the experiments).
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discussed above.
In a rat pup model of BPD, L-arginine becomes a limiting
substrate and disrupts the NO-cGMP signaling pathway,
due to the hyperoxia-induced upregulation of arginase ac-
tivity. The disruption of NO-cGMP signaling reduces the
relaxation of airways as a consequence [4,32]. An increase
of arginase activity has been linked to airway hyperreactivity
under different conditions in different animal models, such
as rat pups, mice, and guinea pigs, as well as in humans
[34,35,37-39]. In the perfused trachea of guinea pigs, it was
demonstrated that increased arginase activity contributes to
the airway hyperresponsiveness after early asthmatic reac-
tion and deficiency of cNOS-derived NO [40]. Marsingh
et al. [41] have shown that the increase of arginase activity
after early asthmatic reaction in guinea pigs impairs the
neuronal nitric oxide-mediated relaxation of ASM. There-




























Figure 8 Effect of in vivo L-citrulline supplementation on TSM relaxat
pups with L-citrulline (200 mg/kg/day) reversed the hyperoxia-induced imp
(p < 0.01). * Hyperoxia + L-citrulline vs. Hyperoxia; *p < 0.05; **p < 0.01 (n= 4 foairways under in vitro and in vivo conditions of TSM
obtained from hyperoxia exposed animals was studied.
Hyperoxia-induced impairment of the relaxant responses of
TSM of rat pups was reversed by L-citrulline supplementa-
tion under both in vitro and in vivo conditions, indicating the
role of L-citrulline/L-arginine recycling enzymes in hyperoxic
conditions. In order to demonstrate that the recovery of the
impaired relaxation of TSM was due to recycling of
L-citrulline into L-arginine, the ASS and ASL were inhibited
using specific inhibitors. Interestingly, the protective effect of
L-citrulline in hyperoxic TSM was lost by the inhibition of
ASS, as well as ASL activity, further confirming the role of
the L-citrulline/L-arginine cycle and the substrate limitation
to NOS. Maarsingh et al. [27] also have found that exogenous
L-citrulline fully reversed the impaired iNANC relaxation in
the guinea pig model of asthma. We have shown that after
hyperoxic exposure, arginase activity increased in the experi-
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r each protocol of the experiments).
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common substrate, contribute to the impairment of relax-
ation in most distal airways because of the decrease of NO
production [4,32].
Since it has been shown that the limitation of L-arginine
availability to NOS is involved in pathogenesis of several
diseases involving NO deficiencies, L-arginine supplemen-
tation to the animals has been used to treat these disor-
ders. We have observed that the supplementation of
300 mg/kg of L-arginine single dose given daily for seven
days through the intraperitoneal route reversed the impaired
relaxant responses in rat pups [32]. Although L-arginine sup-
plementation in rat pups exposed to hyperoxia seems to
normalize impaired relaxation of lung parenchymal strips,
it further increased arginase activity, thus reducing the
effectiveness of L-arginine therapy. In addition, oral
L-arginine administration failed to reduce airway hyperre-
sponsiveness in a murine model of allergic asthma [42] or in
asthmatic patients [43]. This failure might be because of the
presystemic elimination of L-arginine by increased intestinal
or hepatic arginase activity [44].
In contrast, L-citrulline is not taken up by the liver, but is
metabolized predominantly in the kidney to L-arginine and
could be considered as a masked precursor of L-arginine
bypassing the liver [24], thus providing plenty of substrate
for NO-cGMP signaling pathway [45]. The benefits of oral
administration of L-citrulline have been shown in many
diseases. Oral administration of L-citrulline in patients suf-
fering from sickle cell disease raised the decreased plasma
levels of L-arginine without any toxicity [46]. Furthermore,
L-citrulline decreased pulmonary hypertension after surgery
in patients with congenital heart disease [47], and it also
reduced blood pressure response to cold stress [48]. Recently,
Cormio et al. [49] have shown that oral L-citrulline supple-
mentation improves erection hardness in men with mild
erectile dysfunction. Another study revealed that supplemen-
tation of L-citrulline prevents hyperoxia-induced lung injury
in newborn rats [11]. L-citrulline also ameliorates develop-
ment of pulmonary hypertension and increases NO produc-
tion in piglets exposed to chronic hypoxia [50]. These studies
provide evidence that support the use of L-citrulline as a ther-
apy in diseases characterized by NO deficiency.
The animal model used in this study has proven quite
successful to characterize the role of the L-citrulline/
L-arginine cycle under normal and limiting conditions of
NOS substrate. We recognize that this model under in vitro
conditions has limitations, as it is isolated from systemic cir-
culation and lacks the connections from central nervous sys-
tem, which also affect the physiology of airways.
Conclusion
This study demonstrates that the prolonged hyperoxic ex-
posure to new born rats causes impaired relaxation of
tracheal smooth muscle. Supplementation of L-citrullinein vitro and in vivo reverses hyperoxia-induced attenuated
relaxant responses of rat pup TSM in L-arginine limiting
conditions. However, L–citrulline has no effect on relaxation
in basal conditions when L-arginine is not a limiting factor.
The evidence originated from this study suggests that sup-
plementation with L-citrulline may have higher potential
than L-arginine as a therapeutic use for preterm infants at
risk for increased airway reactivity.
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